Gastroenterology
Volume 131, Issue 6 , Pages 2003-2005 , December 2006

Is the Demonstration of Adenoma Reduction With Rofecoxib a Pyrrhic Victory?

  • Patrick M. Lynch

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: Patrick M. Lynch, JD, MD, Associate Professor of Medicine, The University of Texas M.D. Anderson Cancer Center, P.O. Box 301402, Houston, TX 77230-1402. fax: (713) 563-4398.

References 

  1. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal and adenoma in male health professionals. Ann Intern Med. 1994;121:241–246
  2. Chan AT, Giovannucci EL, Schernhammer ES, Colditz GA, Hunter DJ, Willett WC, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern. 2004;140:157–166Med
  3. Cook NR, Lee I-M, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294:47–55
  4. Baron J, Sandler RS, Bresalier RS. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674–1682
  5. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–884
  6. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–895
  7. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? (Meta-analysis of randomized trials). BMJ. 2006;332:1302–1308
  8. Psaty BM, Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. [editorial] N Engl J Med. 2006;355:950–952
  9. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296:1619–1632
  10. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633–1644
  11. Graham DJ. Cox-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. [editorial] JAMA. 2006;296:1653–1656
  12. Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–1952
  13. Peterson SK, Watts BG, McGivern B, Burke S, Latchford A, Phillips R, et al. FAP-affected adults’ responses to reported cardiovascular risks associated with celecoxib. 2005;Presented at Collaborative Group of the Americas on Inherited Colon Cancer (CGA), Salt Lake City, Utah, October
  14. Burke C, Hawk E, Eagle C, Woloj M, Church J, Hasson H, et al. Design and primary safety outcome in a phase I trial of celecoxib in children with FAP. Abstract P29 Familial Cancer. 2005;4(Supp1):77
  15. Lynch P, Burke C, Hawk E, Eagle C, Woloj M, Church J, et al. Colonoscopy in a phase I safety trial of celecoxib in children with FAP. Abstract F42 Familial Cancer. 2005;4(Supp1):57
  16. Information on clinical trials and human research studies. 2006;Available: www.clinicaltrials.gov/. Accessed October 16

PII: S0016-5085(06)02286-4

doi: 10.1053/j.gastro.2006.10.052

Gastroenterology
Volume 131, Issue 6 , Pages 2003-2005 , December 2006

Article Tools